Innovative insights into the effects of a high‐sucrose diet on pancreatic health and the therapeutic role of empagliflozin in type 2 diabetes: An experimental study
Animal Models and Experimental Medicine · 2025
DOI: 10.1002/ame2.70081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, 2025. Verfasst von Emad Gholami und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. Hauptthemen laut MEDLINE: Diet, Carbohydrate Loading, Pancreas, Benzhydryl Compounds, Glucosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 Diabetes (T2D) is a growing global health issue, often aggravated by excessive sugar intake. Chronic high‐sucrose diets contribute to insulin resistance, oxidative stress, and pancreatic dysfunction, worsening metabolic health. Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors, like empagliflozin, show potential in improving glycemic control and metabolic parameters, but their effects on pancreatic efficiency in sugar‐induced T2D are not well understood. This study aimed to explore the effects of empagliflozin on metabolic and pancreatic protection in a high‐sucrose diet‐induced T2D model. Male Wistar rats were divided into four groups: normal, normal‐treated, diabetic, and diabetic‐treated ( n = 8 per group). Diabetes was induced with a 35% sucrose solution for 8 weeks, followed by a low‐dose streptozotocin (STZ) injection. Treated groups received empagliflozin (15 mg/kg/day) for the duration. Biochemical markers, including fasting blood sugar (FBS), lipid profile, insulin levels, and oxidative stress markers, were measured. Insulin resistance (HOMA‐IR) and pancreatic function (HOMA‐B) were assessed. Histological analysis of pancreatic tissues was performed. The high‐sucrose diet increased FBS, insulin resistance, and oxidative stress, while decreasing pancreatic function and islet diameter. Empagliflozin treatment lowered FBS ( p = 0.001), improved insulin sensitivity ( p = 0.001), reduced triglycerides ( p = 0.001), and LDL ( p = 0.05). It also enhanced antioxidant enzymes, reduced lipid peroxidation (MDA, p = 0.001), and preserved pancreatic islet structure ( p = 0.001). A high‐sucrose diet negatively affects metabolic health and pancreatic function. Empagliflozin mitigates these effects by improving metabolism, reducing oxidative stress, and preserving pancreatic integrity, suggesting its potential as a therapeutic agent in diabetes related to excessive sugar consumption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.
- Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran.
- Nervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran.
ORCID-Profile: Habib Yaribeygi
Zitieren
APA
Gholami, E., Fardin, A., Iranshahi, F., Malek, A., Saravani, A., Aghvami, F., Parsaei, H., & Yaribeygi, H. (2025). Innovative insights into the effects of a high‐sucrose diet on pancreatic health and the therapeutic role of empagliflozin in type 2 diabetes: An experimental study. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.70081
Vancouver
Gholami E, Fardin A, Iranshahi F, Malek A, Saravani A, Aghvami F, et al. Innovative insights into the effects of a high‐sucrose diet on pancreatic health and the therapeutic role of empagliflozin in type 2 diabetes: An experimental study. Animal Models and Experimental Medicine. 2025. doi:10.1002/ame2.70081
BibTeX
@article{Gholami2025,
author = {Gholami, Emad and Fardin, Ali and Iranshahi, Fazeleh and Malek, Alireza and Saravani, Ali and Aghvami, Faranaz and Parsaei, Houman and Yaribeygi, Habib},
title = {Innovative insights into the effects of a high‐sucrose diet on pancreatic health and the therapeutic role of empagliflozin in type 2 diabetes: An experimental study},
journal = {Animal Models and Experimental Medicine},
year = {2025},
doi = {10.1002/ame2.70081}
}
EUVIMED